Free Trial

What is Zacks Research's Forecast for Chemours Q2 Earnings?

Chemours logo with Basic Materials background

The Chemours Company (NYSE:CC - Free Report) - Stock analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Chemours in a report issued on Wednesday, July 9th. Zacks Research analyst R. Department now forecasts that the specialty chemicals company will post earnings of $0.40 per share for the quarter, down from their prior estimate of $0.47. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q3 2025 earnings at $0.48 EPS, FY2025 earnings at $1.32 EPS, Q1 2026 earnings at $0.35 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.70 EPS, Q4 2026 earnings at $0.41 EPS, FY2026 earnings at $2.10 EPS, Q1 2027 earnings at $0.49 EPS and FY2027 earnings at $2.44 EPS.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a return on equity of 23.82% and a net margin of 0.54%. The business had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. During the same period in the prior year, the company posted $0.32 earnings per share. The firm's revenue was up .4% on a year-over-year basis.

A number of other analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. The Goldman Sachs Group decreased their price target on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Barclays dropped their price objective on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 28th. UBS Group dropped their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Truist Financial cut their price target on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $17.33.

Read Our Latest Research Report on CC

Chemours Stock Performance

CC traded up $0.28 during midday trading on Thursday, reaching $14.05. The company's stock had a trading volume of 4,852,642 shares, compared to its average volume of 2,526,835. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01. The company has a fifty day simple moving average of $11.32 and a 200 day simple moving average of $14.01. The stock has a market cap of $2.10 billion, a P/E ratio of 13.50 and a beta of 1.65. Chemours has a twelve month low of $9.13 and a twelve month high of $25.54.

Institutional Investors Weigh In On Chemours

A number of hedge funds and other institutional investors have recently made changes to their positions in CC. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Chemours by 18.6% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 12,994 shares of the specialty chemicals company's stock valued at $149,000 after purchasing an additional 2,039 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Chemours by 132.6% during the second quarter. Parallel Advisors LLC now owns 5,634 shares of the specialty chemicals company's stock valued at $65,000 after acquiring an additional 3,212 shares during the last quarter. Inspire Investing LLC raised its position in Chemours by 5.7% during the 1st quarter. Inspire Investing LLC now owns 25,156 shares of the specialty chemicals company's stock worth $340,000 after purchasing an additional 1,357 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Chemours during the first quarter worth about $403,000. Finally, Petrus Trust Company LTA acquired a new stake in Chemours during the 1st quarter valued at approximately $198,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Chemours

In related news, CFO Shane Hostetter purchased 4,450 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the purchase, the chief financial officer owned 59,694 shares in the company, valued at approximately $673,348.32. This represents a 8.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Damian Gumpel bought 13,400 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was purchased at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the transaction, the insider directly owned 123,879 shares of the company's stock, valued at $1,142,164.38. The trade was a 12.13% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 25,672 shares of company stock worth $251,573 in the last three months. 0.47% of the stock is owned by insiders.

Chemours Dividend Announcement

The firm also recently declared a dividend, which was paid on Monday, June 16th. Investors of record on Monday, May 19th were paid a dividend of $0.0875 per share. This represents a dividend yield of 3.17%. The ex-dividend date of this dividend was Friday, May 16th. Chemours's dividend payout ratio (DPR) is 175.00%.

About Chemours

(Get Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Stories

Earnings History and Estimates for Chemours (NYSE:CC)

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

7 Nuclear Stocks One Announcement Away from Exploding

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines